Treatment did not alter the relative abundance of CD3+ T cells, CD4+ helper T cells, CD4+Foxp3+ regulatory T cells, CD8+ effector T cells, cells expressing the T cell activation and exhaustion marker PD-1, B220+ B cells, CD115+ blood monocytes, CD68+ monocytes/macrophages, CD11b+Ly6G+ neutrophils, or CD11b+Ly6C+ monocytes but increased the proportion of F4/80+ differentiated macrophages, potentially in response to the presence of dying tumor cells (Figure 8E). The gene discussed is CD68; the disease is neoplasm.